COLUMBIA, Md.--(BUSINESS WIRE)--Celsion Corporation (NASDAQ: CLSN), a biotechnology drug development company that is leveraging its Heat Sensitive Liposomal Technology platform to encapsulate and deliver high concentrations of proven chemotherapeutics, today announced that it would hold a conference call at 11:00 a.m. Eastern Time on Thursday, December 18, 2008 to discuss its exclusive Japan license agreement for ThermoDox® with Yakult Honsha announced on December 15, 2008.
